| abstract |
The present disclosure relates to solid forms and polymorphs of compound (1): 3-(2,6-difluoro-3,5-dimethoxyphenyl) -l-ethyl-8-(morpholin-4-ylmethyl)-l,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer. |